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Abstract 
Background: The need for immune suppressive strategies in the control of chronic inflammatory bowel diseases originated 
in the 1960s following the perception of a relative inefficacy of salazopyrin and its derivatives. In some 50 years upon an 
anecdotal claim, the indication for thiopurines in the management of inflammatory bowel diseases has come of age. 
Objective: The aim of this minireview is to give an overview, after the historical premises, of the current use of thiopurines 
in the context of inflammatory bowel diseases. 
Method: Through MEDLINE searches, we reviewed the literature of the last two decades. 
Results: For Crohn’s disease, the 1980 trial of 6-mercaptopurine for steroid sparing and fistula closure proved pivotal. 
The analysis of withdrawal experiments and of numerous open trials have established the efficacy of thiopurines for 
ulcerative colitis. In this indication, cutting-edge data are now showing that because targeting dysplasia, thiopurines can 
induce mucosal/histological healing, thus abolishing or delaying the need for pre-emptive (tumor prophylactic) colectomy. 
Conclusion: In UC thiopurines may be recognized to effect a treat-to-target strategy, joining the modern algorithms of 
rheumatologic disorders.  
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1 Introduction 
At the time when the Western World appears to become indwelled by chronically inflamed individuals (“the 
inflammacitizens”) [1], the inflammatory disorders of the bowel have begun to trespass the Western boundaries, invading 
the East with epidemics-like episodes in hitherto unsuspected areas, such as for example the Persian counties [2]. 
   The consequent hustle to refine effective remedies has revealed that the Achilles heel in the treatment of inflammatory 
bowel diseases (IBD) relies with a relative lack, and/or scarce effectiveness of drugs to maintain remission [3]. Begun 
sometime in the 40s, the chase for drugs capable to maintain an effective, yet acceptably toxic control of IBD, was initially 
rewarded by the release of salazopyrin [4] and its mesalamine derivatives [5]. However, despite continuous improvements, 
mesalamines have revealed substantial limits, including an unsatisfactory control of severe ulcerative colitis (UC) [6], 
weak activity in Crohn’s disease (CD) [7], a low but documented tendency to be nephrotoxic [8].  
   IBD is known to mainly present with an acute bout that then tends to settle in a variable time length. Chronicization of 
inflammation may be hypothetically ascribed to a plethora of often intertwined factors, schematically including: 1) 
mucosal damage induced by reactive oxygen species as by-products of the uncoupling of mitochondrial oxidative 
phosphorilation [9]; 2) altered mucosal permeability [10]; 3) genetic biases towards pro-inflammatory cytokine networks, 
promoting a crucially pathogenetic dialogue error between luminal contents and mucosal immune system [11]. Naturally 
occurring regulators of such pro-inflammatory forces do exist, including the action of regulatory T-lymphocytes (T-regs) 
[12], the preferential gut use of antibodies that do not fix complement [13], and the defensive role played by mucus and 
defensins [14]. If prevailing, these factors may cause abortion of the gut inflammatory chain, originating the clinical entity 
called by some “self-limiting colitis” [15]. However, failure is not uncommon as witnessed by commonly reckoned data 
on the natural history of UC: a 50-80% frequency of a swinging course, whereas 15-30% of the patients experiences a 
chronic active course [16] leading to a 10% resort to surgery after 5 years [17]. Often exhibiting an erratic or continuous 
steroid dependence, such patients were classified as indications for long-run immune suppressive regimes by International 
Organizations [18]. Reassured by the extensive rheumatologic experience, a few caretakers adhering to the 
recommendations borrowed methotrexate (MTX) from their rheumatologist pairs to try and maintain remission in their 
IBD subjects [19]. The results of a few trials indicate that MTX can achieve and maintain remission in some CD patients 
[20]; however, its probable inferiority to thiopurines rarely recommends its indication as a first-line drug, unless in CD 
patients with a dominant rheumatologic presentation [21]. No reliable data are so far available on the effectiveness of 
MTX in UC; last but not least, the liver toxicity of MTX (fibrosis) is an important issue [22]. The complex of this data 
therefore advises us to shift our consideration to the thiopurines. 
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   In the 60s, the thiopurines (azathioprine / 6-mercaptopurine) sneaked through these “glitches” to enter the arena of the 
treatment of IBD. 
   The aim of this minireview is to give an overview, after the historical premises, of the current use of thiopurines in the 
context of IBD. 
   Articles published in English on the use of thiopurines in patients with IBD were identified through MEDLINE, 
SCOPUS, ISI-Web of Knowledge, and EMBASE searches using the terms “IBD”, “inflammatory bowel disease”, 
“ulcerative colitis”, “Crohn’s disease”, “thiopurines”, “maintenance therapy”, “immune suppression”, “6-mercaptopurine” 
and “azathioprine”. The start date was 1980 and the final date of the search was April 15, 2018. Reference lists from 
published articles were also employed. Titles of these publications and their abstracts were scanned in order to eliminate 
duplicates and irrelevant articles. Two authors (G.C.A. and D.G.R.) independently reviewed the literature search’ results 
and selected relevant studies. The full-text studies were assessed by the two authors to determine whether the inclusion 
criteria were met (Figure 1). 
 
Figure 1 Study screening and selection. 
 
1.1 Thiopurine Metabolism 
The thiopurines are purine analogues that were initially proposed by the Nobel Prize winners Elion and Hitching for the 
treatment of hematologic malignancies [23]. 
   For short, the pro-drug azathioprine (AZA) undergoes non-enzymatic conversion to the active molecule 6-
mercaptopurine (6-MP) at the liver level. A number of horizontal steps then metabolize 6-MP to 6-thioguanine nucleotide 
(6-TGN), the effectors of the cytoreductive actions at the basis of the original hematologic indications of the thiopurines. 
Two crucial side-pathways governed by thiopurine methyl-transferase (TPMT) and xanthine oxydase (XO) may 
respectively produce methyl-mercaptopurine (MMP) or thiouric acid. Such enzymes have been exploited as the targets 
of a number of effective strategies to modulate thiopurine metabolism [24].  
 
2 Historical Notes  
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The anecdotic use of 6-MP for UC has been reported as early as 1962 [25]. For roughly 30 years, the evidence of the 
effectiveness of AZA/6-MP for this disorder has been based on withdrawal experiments [26].  
   Focusing on CD, a pivotal double-blind study by Present et al., in 1980 demonstrated the activity of 6-MP in fistula 
closure and steroid sparing for patients with severe disease [27]. An exhaustive overview of the indications for thiopurines 
in IBD has recently appeared [28]. 
   Evidence from both exhaustive clinical practice and designed trials indicates that thiopurines are best effective if 
introduced soon after achieving disease remission on any “acute” drug, whether steroids, cyclosporine, or anti-Tumor 
Necrosis Factor (TNF) biological [29], with their full action recognizing a lag of up to 17 weeks [30]. This clinical tenet 
is consistent with the basic-science knowledge that thiopurines effect their immune suppressive action on a two-hit basis: 
the initial hit simply arrests cell mitosis, the second one then abolishes the memory T-cell pool [31]. As the consequence, 
early withdrawal will likely lose disease control (as shown by our own data above), whereas no signs of drug effectiveness 
are to be expected during the lag time. Further to such points, addition of thiopurines to acute drugs (for example steroids) 
and for a short bout must logically be predicted to be doomed to failure; in other words, top-down strategies are not 
indicated in this setting [32,33]. Consistently, official recommendations discourage the use of thiopurine monotherapy to 
achieve remission [34]. 
 
3 Recent Approaches 
In 2009, we reported our long-term follow-up study (some patients were treated until to 201 months) showing that 
breakthrough phenomena were relatively infrequent (28%) and was observed at a median time of 12 months; despite 
treatment, 4 colectomies were required [35]. In the same year, a large withdrawal study reported that after AZA 
withdrawal, a third of the patients relapsed within 12 months, half within 2 years and two-thirds within 5 years [36].   
Finally, in 2015, we dealt with the issue of intolerance to AZA. We retrieved 85 AZA prescriptions for 42 UC, 37 CD, 
and 6 miscellaneous patients. In this sample, there were 10 episodes of gastric intolerance to AZA, which were switched 
to 6-MP: 6 out of 10 (60%) responded and tolerated the switch drug in a median follow-up of 66 months [37].   
   Though concentrated on UC, the results of several studies confirm the crucial role played by thiopurines in the 
management of the IBDs. This concept is verified in terms of numbers, wherein modern series (Table 1 and Table 2) 
indicate a sensibly increased rate of use as compared to previous data. The nature itself of the chronic inflammatory 
affections, namely the capacity to continuously refuel the inflammatory activity in the absence of a recognizable etiologic 
agent required to plan the lifelong use of drugs able to curtail few or more steps of the inflammatory process at an 
acceptable toxicity toll. Intriguingly, retrospective analysis of a 50-year experience, has left limited doubts as to the 
effectiveness of AZA/6-MP, yet duly, has opened the ground for more exciting questions; a few of these regard the 
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positioning of thiopurines in the algorithms, and whether thiopurines can actually impact disease history. A one-year 
survey from our outpatient clinic, including 88 patients with IBD, confirmed the effectiveness of thiopurines. In fact, only 
the resected subjects or those with left-confined disease remained in remission without these drugs [38]. Recently, in a 
Swedish study, Eriksson et al. have approached the issue by uniquely comparing UC patients tolerant and intolerant to 
thiopurines. As the result, the robust evidence was achieved that disease history does turn out modified by the consistent 
use of these drugs. In fact, the cumulative probability of colectomy within 10 years was significantly higher (p<0.01) in 
intolerant (29%) than in tolerant patients (19.5%). A similar difference was evident considering the probability of hospital 
admission (p<0.01), the risk of progression of disease extent (p=0.07) and the rate of patients receiving anti-TNF therapy 
(p=0.03) [39].   
   The evidence from both our small series (Table 1 and Table 2) [35] and the larger withdrawal study [36] indicate that 
early withdrawal for toxicity specifically leads to relapse and colectomy.  
 
Table 1 The 2009 study including 38 patients with moderate/severe ulcerative colitis: follow-up [35]. 
Patients 38 moderate/severe UC 
% no colectomy 62 
% withdrawn 1-72 months 57 
% continued 4-121 months 15 
% breakthrough 26 
 
Table 2 The 2009 study including 38 patients with moderate/severe ulcerative colitis: perturbing events [35]. 
Early Withdrawal (N:12) Late Withdrawal (N: 10) Breakthrough (N: 10)  
< 7 months 7-12 months 3-48 months  
12/12 4/10 - Toxicity 
9/12 1/10 4/10 Colectomy 
 
The clinician facing such a problem may be left with two alternatives: he/she may either begin the patient on a reduced 
dose (50 mg for example) to be progressively increased, or genetically test the patient’s TPMT, looking for low enzyme 
variants at risk for leucopenia. A uniform recommendation as to this issue has not yet been released. In a previous study, 
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we examined the most efficacious policies that are used to react to events impacting regular thiopurine administration, 
including switch to 6-MP to respond to frequent rise of AZA gastric intolerance. In particular, 60% of cases of AZA 
intolerance responded to switch to 6-MP [37]. Hence, a trial with 6-MP is worth doing in cases of intolerance to AZA. 
3.1 Feasibility of long-term treatments 
In the cited series the range of thiopurine exposure was between 1 and >16 years. Some of our patients have now received 
these drugs for 20 years. Full monitoring of toxicity, including rise of non-melanoma skin cancer has so far been negative 
[35].  
3.2 Hospitalization reduction 
The ability of thiopurines to reduce hospitalization is being actively investigated. One-hundred percent of 10 patients 
withdrawn from AZA for intolerance or toxicity had their relapse treated in hospital. Of further 16, regularly treated with 
AZA after a hospitalization, 11 have then been continued on AZA with no further admissions (unpublished data).  
Notably, avoidance of hospitalization and less-than expected malignancy frequency may be seen as the clinical mirror of 
the thiopurine –dependent mucosal healing, as discussed below.  
   It is highly due to acknowledge that the indication for thiopurines in IBD has shown a relentless increase in the years: 
the percentage figures of their use in the period 1984-2006 range between 12 and 29% (Table 3) [40-43], in contrast with 
the frequency of 52% in our hands [38], and the 78% claimed in Kirschgesner et al. work [44] dating to 2009-2014.  
 
Table 3 A list of large studies giving rates of thiopurine use and study time lags.  
Study Team  % Thiopurine use Study Period 
Margagnoni et al [40] 12.4 1984-2008 
Saibeni et al [41] 16 Before 2008 
Fraser et al [42] 28 1968-1999 
Bardhan et al [43] UC: 16  CD: 29 Censored 10-2006 
Actis et al [38] 52 2008-2009 
Kirschgesner et al [44] 
Eriksson et al [39] 
UC: 78  CD: 69 
25.1 
2009-2013 
End follow-up 12-2015 
UC: ulcerative colitis; CD: Crohn’s disease. 
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   A stimulating discussion may derive from the hint in our unpublished series that need for hospital admission can be 
reduced if patients are placed on thiopurines after the initial attack. What looked like a drug’s capacity to alter the disease 
clinical history, remained in wait for the subtle demonstration that thiopurines can achieve “tight control of objective 
signs of inflammation halting disease progression” [45]. Indeed, recent controlled trials have looked at mucosal healing 
as a measure of inflammation suppression. Post-hoc analysis of the SONIC trial (looking at anti-TNF therapy for CD) 
has revealed that thiopurine monotherapy can achieve mucosal healing in 19% of the cases [46]. This data has now been 
implemented by the recent demonstration, in UC patients, that AZA monotherapy can obtain mucosal healing in 43%, 
and histological healing in 38% of the cases [47], meeting the unexpressed wishful thinking in Allen’s paper [45], and 
implicating the added value that AZA monotherapy in UC can avoid or delay pre-emptive colectomy thanks to the control 
of otherwise unchecked dysplasia [48], achieving eventual chemoprevention [49].  Similar data are now freshly coming 
from Scandinavia, where the figures of thiopurine prescriptions, 7% between 1976 and 1990, had risen to 34% in 1991-
2005, whereas the indication for colectomy got restrained consensually [50].  
   This finding, saluted by Burton Korelitz [51] as a revitalization of thiopurines, in fact solidly hints that the old 
thiopurines do deserve (on the rheumatologists’ footprints) to enter the list of the drugs that can pursue the treat-to-target 
goal in IBD. Thus, recent proposals to merely position thiopurines as ancillary drugs to reduce monoclonal anti-TNF 
antigenicity [52], become mitigated by such fresh findings.  
   Apart from this newly opened scenario, one may observe that decades after the award of the Nobel Prize to Elion and 
Hitchins the thiopurines do not cease to raise the attention of patients, physicians, and researchers [53].  
   Considering thiopurine positioning in the IBD maintenance algorithm the following considerations should be taken into 
account. 
   There is no solid evidence as to when safely discontinue thiopurines in an IBD in remission [54]. A few authors have 
recommended that thiopurines be continued until deliberately achieving moderate (3.5-4 white blood cells per microliter) 
leucopenia as the guarantee of full remission [55]; of course, this is a subjective decision that depends on physician’s 
wisdom and skills. The weak tendency to induce certain malignancies (non-melanoma skin cancer) [56] can be monitored, 
and is outweighed by the ability of thiopurines to lead to mucosal healing with a chemopreventive effect on colon cancer 
[49]. The combination thiopurines plus biologicals is better than either alone to control the two IBD phenotypes, and 
thiopurines can significantly reduce formation of antibodies to the hybrid antibody protein [52].  
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4 Conclusion 
In a world where pharmacological options for IBD treatment seem to be unavoidably dominated by biological drugs, the 
classic yet traditional indications for thiopurines (steroid sparing, remission maintenance, avoidance of post-operative 
recurrence in CD) seem to become revitalized by the introduction of thiopurines into demanding treat-to-target paradigms 
on the rheumatologists’ footsteps. For instance, these concepts may find their application in the data of the CALM study, 
where in patients under steroids and anti-TNF monoclonals (escalated on the basis of the Crohn’s Disease Activity Index, 
fecal calprotectin, C-reactive protein) fared yet better when mucosal inflammation control was achieved in response to 
the addition of an “old” thiopurine [57].   
 
5 List of Abbreviations 
6-MP = 6-mercaptopurine  
6-TGN = 6-thioguanine nucleotide  
AZA = azathioprine  
CD = Crohn’s disease   
IBD = inflammatory bowel diseases   
MMP = methyl-mercaptopurine  
MTX = methotrexate  
TNF = anti-Tumor Necrosis Factor  
TPMT = thiopurine methyl-transferase  
UC = ulcerative colitis 
XO = xanthine oxydase  
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